E2F4 and cancer: We systematically interrogated the Cancer Therapeutics Response Portal datasets, and found that E2F4 expression correlated with resistance to ferroptosis inducers ((RSL3, ML210 and ML162, which inhibit GPX4 activity) (Fig. 5K).